Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity

Antiviral treatments inhibiting Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication may represent a strategy complementary to vaccination to fight the ongoing Coronavirus disease 19 (COVID-19) pandemic. Molecules or extracts inhibiting the SARS-CoV-2 chymotripsin-like protease (3CL(Pro)) could contribute to reducing or suppressing SARS-CoV-2 replication. Using a targeted approach, we identified 17 plant products that are included in current and traditional cuisines as promising inhibitors of SARS-CoV-2 3CL(Pro) activity. Methanolic extracts were evaluated in vitro for inhibition of SARS-CoV-2 3CL(Pro) activity using a quenched fluorescence resonance energy transfer (FRET) assay. Extracts from turmeric (Curcuma longa) rhizomes, mustard (Brassica nigra) seeds, and wall rocket (Diplotaxis erucoides subsp. erucoides) at 500 mu g mL(-1) displayed significant inhibition of the 3CL(Pro) activity, resulting in residual protease activities of 0.0%, 9.4%, and 14.9%, respectively. Using different extract concentrations, an IC50 value of 15.74 mu g mL(-1) was calculated for turmeric extract. Commercial curcumin inhibited the 3CL(Pro) activity, but did not fully account for the inhibitory effect of turmeric rhizomes extracts, suggesting that other components of the turmeric extract must also play a main role in inhibiting the 3CL(Pro) activity. Sinigrin, a major glucosinolate present in mustard seeds and wall rocket, did not have relevant 3CL(Pro) inhibitory activity; however, its hydrolysis product allyl isothiocyanate had an IC50 value of 41.43 mu g mL(-1). The current study identifies plant extracts and molecules that can be of interest in the search for treatments against COVID-19, acting as a basis for future chemical, in vivo, and clinical trials.

Automated summary

Research has identified plant extracts and molecules as potential treatments for COVID-19, laying the groundwork for future chemical, in vivo, and clinical trials.